Diabetic retinopathy is an important complication of diabetes and a major reason healthcare organizations continue to focus on improving access to routine retinal screening. The challenge is not simply identifying patients who should be screened. Health plans and providers must also make it easier for patients to complete recommended eye assessments and ensure that actionable results are available efficiently.
Advances in AI-powered fundus cameras are helping change how diabetic retinopathy screening can be delivered. By combining portable retinal imaging with artificial intelligence, healthcare organizations can bring screening closer to the patient and potentially incorporate it into settings where patients are already receiving care.
Instead of relying exclusively on traditional referral pathways, point-of-care retinal imaging creates an opportunity to identify diabetic retinopathy during routine healthcare encounters and connect patients who need additional care with the appropriate next step.
Why Diabetic Retinopathy Screening Matters
Diabetic retinopathy develops when diabetes damages blood vessels in the retina. Because retinal changes can develop before a patient recognizes significant changes in vision, appropriate screening plays an important role in identifying disease and determining when further evaluation is necessary.
For healthcare organizations, however, recommending a screening does not guarantee that the screening will be completed.
Patients may need to schedule a separate appointment, travel to another healthcare facility, take additional time away from work, or navigate another referral. Each additional step can create an opportunity for the screening to remain incomplete.
Making diabetic retinopathy screening more accessible at the point of care can help reduce some of those barriers.
That is where portable fundus imaging and autonomous artificial intelligence become particularly valuable.
What Is an AI-Powered Fundus Camera?
A fundus camera captures images of the interior surface of the eye, including the retina. These retinal images can provide information used to identify signs associated with diabetic retinopathy.
Traditional retinal imaging equipment has often been associated with specialized eye-care environments. Newer handheld technology provides healthcare organizations with a much more portable approach.
BeamMed’s Fundus Camera, for example, combines a compact handheld camera with a cloud-based artificial intelligence diagnostic service. The system captures high-resolution digital fundus images and sends them to AI for interpretation.
The camera is non-mydriatic, meaning imaging can be performed without routinely requiring pharmacological pupil dilation. Autofocus and automatic exposure also help simplify image acquisition.
Once the retinal images have been captured, artificial intelligence analyzes them for signs of diabetic retinopathy.
This combination of portable imaging and autonomous AI interpretation can transform retinal screening from a specialized workflow into something that can potentially be incorporated into a wider variety of healthcare environments.
Bringing Retinal Screening to the Point of Care
One of the most significant advantages of portable fundus imaging is flexibility.
A handheld device does not require the same physical footprint as traditional desktop retinal imaging equipment. This allows healthcare organizations to consider diabetic eye screening in primary care practices, clinics, mobile health programs, community healthcare settings, and other locations where patients with diabetes already receive care.
The ability to perform screening during an existing healthcare encounter can be especially valuable.
Rather than telling a patient that another appointment must be scheduled elsewhere, a healthcare organization may be able to address the screening opportunity while the patient is already present.
That can create a more convenient patient experience while helping organizations address important preventive and quality-care objectives.
How Artificial Intelligence Changes the Screening Workflow
Capturing a retinal image is only one part of the process. The image must also be interpreted.
This is where AI-powered technology creates an important distinction.
BeamMed’s solution uses a cloud-based artificial intelligence service to analyze fundus images and provide real-time detection of more-than-mild diabetic retinopathy. According to BeamMed, the system requires only one image from each eye and can provide results in less than 60 seconds.
The ability to receive an immediate result can simplify the workflow considerably.
A typical process can include:
- Identify an eligible patient who needs diabetic retinal screening.
- Capture a fundus image from each eye using the handheld camera.
- Securely transmit the images to the cloud-based AI service.
- Receive the AI-generated screening result.
- Use the result to determine the appropriate next step in the patient’s care.
This creates a fundamentally different experience from workflows that depend on sending images elsewhere and waiting for interpretation.
Why Speed Matters in Diabetic Eye Screening
Fast results are not simply a matter of convenience.
When screening and results can occur within the same healthcare encounter, providers have an opportunity to discuss the result with the patient while they are still present.
If the screening does not indicate a concerning result, the completed assessment can become part of the patient’s documented care.
When the result indicates that additional evaluation is appropriate, the healthcare team can begin discussing follow-up rather than waiting for a later report.
Closing the loop between screening, results, and appropriate follow-up is an important part of creating an effective preventive-care workflow.
The objective is not to replace comprehensive eye care. Instead, accessible retinal screening can help identify patients who may require additional evaluation while making screening easier to incorporate into routine care.
Reducing Barriers Through Non-Mydriatic Imaging
Another important development is the ability to capture retinal images without routinely dilating the patient’s pupils.
Pupil dilation can add time and inconvenience to an examination. Patients may experience temporary light sensitivity or blurred vision, which can affect their ability to immediately return to normal activities.
Non-mydriatic imaging can make the screening experience more convenient because images can be captured without this additional step.
For organizations trying to incorporate diabetic eye screening into primary care or other routine healthcare settings, reducing workflow complexity is important.
The easier a screening is to perform, the more practical it becomes to integrate into existing patient encounters.
Expanding Who Can Perform Diabetic Retinopathy Screening
Portability alone does not necessarily solve an access problem. Technology also needs to be practical for the healthcare professionals expected to use it.
BeamMed states that its solution is designed so diabetic retinopathy screening can be performed by trained healthcare professionals during routine patient examinations.
Features such as autofocus and autoexposure help simplify image acquisition, while autonomous AI handles interpretation.
This model can potentially expand the number of healthcare environments capable of offering retinal screening without requiring every location to operate as a specialized ophthalmology practice.
That distinction can be especially important for health systems, primary care organizations, health plans, and community-based programs attempting to reach larger diabetic populations.
Supporting Healthcare Quality and Closing Care Gaps
Diabetic eye screening is also relevant to healthcare quality initiatives.
Health plans and providers continually work to identify patients who have outstanding preventive and chronic-care needs. The challenge is converting those identified gaps into completed care.
Point-of-care technology provides another strategy.
If an eligible patient is already visiting a participating healthcare location, retinal screening may be incorporated into that encounter rather than remaining an outstanding referral.
This can help healthcare organizations create a more integrated approach to diabetic care—one in which screening opportunities are identified and addressed closer to where patients already receive services.
For organizations focused on quality measures, Stars performance, HEDIS initiatives, and population health, technologies that make preventive assessments easier to complete can become an important part of a broader care-gap strategy.
Portable Technology Can Help Reach More Patients
A handheld fundus camera also creates opportunities beyond a conventional medical office.
Portable technology can potentially support screening programs across multiple locations without requiring a large piece of dedicated imaging equipment at every site.
Depending on an organization’s model, this flexibility can support centralized programs, satellite clinics, community outreach, mobile programs, and other distributed healthcare environments.
The common objective is straightforward: bring screening closer to the patient instead of requiring every patient to travel to the screening technology.
That shift can be particularly meaningful for populations facing transportation, scheduling, geographic, or healthcare-access barriers.
AI-Powered Fundus Imaging from BeamMed
BeamMed’s Fundus Camera brings together handheld retinal imaging, cloud connectivity, and autonomous artificial intelligence to help healthcare organizations expand access to diabetic retinopathy screening.
The FDA-cleared and clinically validated solution captures high-resolution fundus images without dilation and uses AI to detect more-than-mild diabetic retinopathy. BeamMed reports sensitivity and specificity greater than 90%, with only one image required from each eye and results available in less than 60 seconds.
For healthcare providers and organizations working to improve diabetic eye screening, close care gaps, and make preventive services easier for patients to complete, portable AI-powered retinal imaging offers a new approach to delivering screening where patients already receive care.
Learn more about the BeamMed Fundus Camera and how AI-powered retinal imaging can support diabetic retinopathy screening at the point of care.
Frequently Asked Questions
What is an AI-powered fundus camera?
An AI-powered fundus camera captures detailed digital images of the retina and uses artificial intelligence to analyze those images for specific signs of eye disease. BeamMed’s system combines a handheld fundus camera with a cloud-based AI diagnostic service designed to detect more-than-mild diabetic retinopathy.
Does a fundus camera require pupil dilation?
Not necessarily. Non-mydriatic fundus cameras are designed to capture retinal images without routinely requiring pharmacological pupil dilation. BeamMed’s Fundus Camera provides non-mydriatic imaging, which can help make retinal screening easier to incorporate into routine patient visits.
How quickly can an AI fundus camera provide diabetic retinopathy screening results?
Processing time varies by system. BeamMed’s AI-powered Fundus Camera is designed to provide results in less than 60 seconds after the required retinal images are captured, supporting point-of-care screening and faster clinical decision-making.
Can an AI fundus camera be used in a primary care setting?
Yes. AI-powered retinal imaging can expand diabetic eye screening beyond traditional ophthalmology settings. BeamMed’s solution is designed so trained healthcare professionals can perform screening during routine patient examinations, making the technology applicable to primary care and other healthcare environments.
How can AI fundus cameras help improve diabetic retinopathy screening?
AI fundus cameras can make retinal screening more accessible by combining portable image capture with automated analysis. This can allow healthcare organizations to perform screenings where patients already receive care, obtain rapid results, and identify patients who may need appropriate follow-up or further eye evaluation.
